These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22269278)

  • 21. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of aromatic enones related to curcumin.
    Robinson TP; Hubbard RB; Ehlers TJ; Arbiser JL; Goldsmith DJ; Bowen JP
    Bioorg Med Chem; 2005 Jun; 13(12):4007-13. PubMed ID: 15911313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities.
    Hong S; Kim J; Seo JH; Jung KH; Hong SS; Hong S
    J Med Chem; 2012 Jun; 55(11):5337-49. PubMed ID: 22575050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.
    Burns CJ; Fantino E; Powell AK; Shnyder SD; Cooper PA; Nelson S; Christophi C; Malcontenti-Wilson C; Dubljevic V; Harte MF; Joffe M; Phillips ID; Segal D; Wilks AF; Smith GD
    J Pharmacol Exp Ther; 2011 Dec; 339(3):799-806. PubMed ID: 21917561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
    Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
    Wong TW; Lee FY; Emanuel S; Fairchild C; Fargnoli J; Fink B; Gavai A; Hammell A; Henley B; Hilt C; Hunt JT; Krishnan B; Kukral D; Lewin A; Malone H; Norris D; Oppenheimer S; Vite G; Yu C
    Clin Cancer Res; 2011 Jun; 17(12):4031-41. PubMed ID: 21531814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YM-201627: an orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Matsuhisa A; Kudoh M; Shibasaki M
    Cancer Lett; 2006 Jul; 238(1):119-27. PubMed ID: 16095812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of 2,5-diaminobenzamide derivatives as anti-proliferating agents.
    Lee SH; Park JW; Hong JE; Park JW; Lee J
    Arch Pharm Res; 2009 Jun; 32(6):803-12. PubMed ID: 19557356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
    Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
    J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
    Panopoulou E; Murphy C; Rasmussen H; Bagli E; Rofstad EK; Fotsis T
    Cancer Res; 2005 Mar; 65(5):1877-86. PubMed ID: 15753386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
    Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
    Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization.
    Yasui M; Yamamoto H; Ngan CY; Damdinsuren B; Sugita Y; Fukunaga H; Gu J; Maeda M; Takemasa I; Ikeda M; Fujio Y; Sekimoto M; Matsuura N; Weinstein IB; Monden M
    Clin Cancer Res; 2006 Aug; 12(15):4720-9. PubMed ID: 16899623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
    Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of benzothiazole derivatives as potent antitumor agents.
    Yoshida M; Hayakawa I; Hayashi N; Agatsuma T; Oda Y; Tanzawa F; Iwasaki S; Koyama K; Furukawa H; Kurakata S; Sugano Y
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3328-32. PubMed ID: 15955697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.